XML 76 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborations (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2014
Oct. 31, 2013
Dec. 31, 2009
Jun. 30, 2001
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Oct. 01, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           $ 1,199.9 $ 833.7 $ 808.1  
Revenue         $ 6,160.7 $ 5,658.0 $ 5,824.3 $ 5,228.3 $ 5,760.5 $ 5,191.7 $ 5,404.8 $ 4,865.1   22,871.3 21,222.1 19,958.7  
Research and development                           5,281.8 5,243.9 4,796.4  
Acquired in-process research and development         $ 50.0 $ 205.0 $ 0.0 $ 857.6 $ 30.0 $ 0.0 $ 0.0 $ 0.0   1,112.6 30.0 535.0  
Trajenta                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           537.9 436.6 356.8  
Tanezumab                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Acquired in-process research and development                               200.0  
Jardiance (BI)                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           447.5 201.9 60.2  
Europe                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Revenue                           3,943.2 3,768.1 3,943.6  
JAPAN                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Revenue                           2,419.7 2,330.9 2,033.1  
Milestone Payments, Sales-based | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms     $ 150.0                            
Milestone Payments, Sales-based | Tanezumab                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms   $ 1,230.0                              
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Trajenta                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           446.4      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Jardiance                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           299.5      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Basaglar                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           (250.0)      
Milestone Payments, Development and Regulatory, Capitalized | Basaglar                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           0.0 (187.5) 0.0  
Profit And Development And Marketing Share | Effient                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations percent (in percentage)       50.00%                          
Sales Reported | Erbitux                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations percent (in percentage)                         38.00%        
Research And Development Exp | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations percent (in percentage)     30.00%                            
Milestone Payments, Development and Regulatory, Expensed | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Research and development                           30.0 55.0    
Milestone Payments, Development and Regulatory, Expensed | Lanabecestat                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Research and development                           50.0 100.0    
Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Europe | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           65.0      
Milestone Payments, Development and Regulatory, Capitalized (Deferred) | JAPAN | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms                           15.0      
Milestone Payments, Development and Regulatory | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms     $ 250.0                            
Milestone Payments, Development and Regulatory | Tanezumab                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms   $ 350.0                              
Milestone Payments, Development and Regulatory | Lanabecestat                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms $ 300.0                                
Milestone Payments, Development and Regulatory, First Indication | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations, terms     $ 100.0                            
Royalty Payments Received | Olumiant                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaborative arrangement, rights and obligations percent (in percentage)     20.00%                            
Erbitux Acquisition                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Marketed products                                 $ 602.1
Deferred tax asset                                 232.2
Deferred tax liability                                 (228.2)
Other assets and liabilities - net                                 57.2
Total identifiable net assets                                 663.3
Total consideration - contingent consideration liability                                 $ (663.3)
Pro forma revenue                               20,200.0  
Erbitux Acquisition | Erbitux                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Pro forma revenue                               735.0  
Human pharmaceutical products                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Revenue                           19,785.7 18,063.9 16,777.7  
Human pharmaceutical products | Erbitux API                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Net product revenue                           0.0 0.0 23.3  
Human pharmaceutical products | Erbitux                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           97.7 100.0 309.4  
Net product revenue                           548.2 587.0 152.3  
Revenue                           645.9 687.0 485.0  
Human pharmaceutical products | Trajenta                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           537.9 436.6 356.8  
Human pharmaceutical products | Effient                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Revenue                           388.9 535.2 523.0  
Human pharmaceutical products | Jardiance                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration and other revenue                           447.5 201.9 60.2  
Human pharmaceutical products | Basaglar                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Revenue                           $ 432.1 $ 86.1 $ 11.1